Japan-based Toshiba has entered into a strategic partnership with Belgium-based Ion Beam Applications (IBA) to expand access to an advanced particle therapy across the globe.

Under the deal, Toshiba Medical Systems will distribute Proteus ONE in Japan, IBA’s compact single-room proton therapy solution and IBA will supply Toshiba’s Carbon Therapy Solutions outside Japan.

Ion Beam Applications CEO Olivier Legrain said: "This is an important step for IBA. A closer collaboration with a company of Toshiba’s caliber and leadership will accelerate the expansion of proton therapy in Japan and the introduction of Toshiba’s carbon therapy across the world.

"Through this new collaboration, IBA will further strengthen its world leading position in proton therapy and will reaffirm its leading position in the delivery of the latest innovative cancer therapies worldwide."

The collaboration will also allow both firms to expand their operation and maintenance (O&M) services.

In addition, the companies will partner on activities such as customer education for ProteusONE and Toshiba’s carbon therapy solutions.